Browse studies, page 1094
Page 1094 of 1,197, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes JAMA Internal Medicine, 2025
- SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2 Cellular and Molecular Life Sciences, 2025
- Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial European Heart Journal, 2025
- Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: The EMPEROR Program Journal of the American College of Cardiology, 2025
- Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial Cardiovascular Diabetology, 2025
- Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial Nature Medicine, 2025
- COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics Nephrology, Dialysis and Transplantation, 2025
- The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial BMC Endocrine Disorders, 2025
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes New England Journal of Medicine, 2016
- Empagliflozin after Acute Myocardial Infarction New England Journal of Medicine, 2024
- Empagliflozin in Patients with Chronic Kidney Disease New England Journal of Medicine, 2022
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes New England Journal of Medicine, 2025
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure New England Journal of Medicine, 2020
- Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes New England Journal of Medicine, 2015
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction New England Journal of Medicine, 2021
- Association between SGLT2 inhibitors and reporting of phimosis/paraphimosis: a comparative pharmacovigilance analysis of the WHO database Acta diabetologica, 2026
- Empagliflozin's Effects on Carotid Ultrasound Parameters in Type 2 Diabetes Patients Post-ST-Elevation Myocardial Infarction: A Randomized Controlled Trial Iranian journal of medical sciences, 2026
- Empagliflozin and renal histological changes in an experimental model of heart failure in male rats Physiological reports, 2026
- The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease Revista da Associacao Medica Brasileira (1992), 2026
- Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026
- Sex-specific modulation of gut microbiota by empagliflozin contributes to renoprotection in diabetic kidney disease mice Frontiers in microbiology, 2026
- Combination of empagliflozin with curcumin attenuates hepatic inflammation in high-fat diet-fed mice via macrophage polarization remodeling and NF-κB modulation Journal of diabetes and metabolic disorders, 2026
- A pharmacovigilance study of sodium-glucose co-transporter 2 inhibitors: adverse events in type 2 diabetic patients having heart failure with reduced ejection fraction 2026
- Targeted metabolomics to assess positive effects of empagliflozin in a Parkinson's disease model – focused on the kynurenine pathway and oxidative stress Scientific Reports, 2026
- Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease Journal of clinical medicine, 2026
- Early-Onset Euglycemic Diabetic Ketoacidosis Following Empagliflozin Initiation Triggered by Acute Influenza and a Ketogenic Diet Cureus, 2026
- Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction medRxiv : the preprint server for health sciences, 2026
- Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study BMC nephrology, 2026
- Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial JACC. Heart failure, 2026
- Empagliflozin in ADPKD with suspected IgA nephropathy: antiproteinuric response without adverse events BMC nephrology, 2026
- Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study British journal of clinical pharmacology, 2026
- Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation Diabetes, obesity & metabolism, 2026
- Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression Basic research in cardiology, 2026
- Mesenchymal stem cells and empagliflozin: a potential therapeutic approach for autophagy and Klotho modulation in diabetic kidney disease Stem cells (Dayton, Ohio), 2026
- Distinct Temporal Modulation of Mesenchymal Stem Cells and Empagliflozin on Renal c-Kit Cells in Diabetic Kidney Disease Frontiers in bioscience (Landmark edition), 2026
- Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease Diabetes, obesity & metabolism, 2026
- Organ-Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models Journal of the American Heart Association, 2026
- Effects of Empagliflozin Combined with Anaerobic, Aerobic, and Endurance Swimming Protocols on Cardiac Structure and Electrophysiology in Healthy Rats Journal of clinical medicine, 2026
- Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease Frontiers in pharmacology, 2026
- Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study Therapeutic advances in endocrinology and metabolism, 2026
- Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial Diabetes care, 2026
- Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage Cardiovascular diabetology, 2026
- Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin PloS one, 2026
- Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review Diabetes technology & therapeutics, 2026
- Empagliflozin Alleviates Renal Ischemia-Reperfusion Injury by Targeting AMPK/NLRP3 Signaling Transplantation proceedings, 2026
- The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany Cost effectiveness and resource allocation : C/E, 2026
- Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era Endocrinology, diabetes & metabolism, 2026
- Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease ( MASLD ): A Systematic Review and Meta‐Analysis Endocrinology, diabetes & metabolism, 2026
- Empagliflozin preserves cardiac function and modulates metabolism in a mouse model of Duchenne muscular dystrophy bioRxiv : the preprint server for biology, 2026
- Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026
- Empagliflozin Reduces Post-Myocardial Infarction Inflammation via BDH1/β-Hydroxybutyrate-Mediated NF-κB Modulation in Macrophages and the Heart Journal of cardiovascular pharmacology, 2026
- Empagliflozin attenuates PTZ-induced neurotoxicity and enhances the protective effects of levetiracetam: Associations with NRF2/GPX4 and AMPK/ULK1/ LC3-II signaling Neurotoxicology, 2026
- Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure BMC cardiovascular disorders, 2026
- Empagliflozin inhibits cardiac hypertrophy via a mechanism involving integrin signalling British journal of pharmacology, 2026
- Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fournier Gangrene: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database American journal of therapeutics, 2026
- Empagliflozin, Linagliptin, and Metformin Differentially Affect Renal PI3K/Akt and MAPK/ERK Signaling Pathways in db/db Diabetic Mice International journal of molecular sciences, 2026
- Empagliflozin Prevents Cardiac Arrest-Induced Renal Injury Through BHB-Dependent Mitoribosome Maintenance International journal of molecular sciences, 2026
- Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study Cardiovascular diabetology, 2026
- Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis European journal of heart failure, 2026
- Cardioprotective properties of empagliflozin and other SGLT2 inhibitors Nature reviews. Cardiology, 2026
- Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial Cardiovascular diabetology, 2026
- Cardiac SGLT2 Expression and Cell-Type-Specific Responses to Empagliflozin in iPSC-Derived Models of Diabetic Cardiomyopathy Journal of cardiovascular development and disease, 2026
- Longitudinal Assessment of Diastolic Function and Myocardial Strain in Type 2 Diabetes: A Comparison of Empagliflozin and Linagliptin Anatolian journal of cardiology, 2026
- Unexpected Insulinoma in Type 2 Diabetes During Long-term Dulaglutide Therapy: A Case Report and Literature Review 2026
- Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart valve surgery: a double-blind, randomized, placebo-controlled trial Indian journal of thoracic and cardiovascular surgery, 2026
- Empagliflozin Improves Atherosclerosis by Promoting Mitophagy in Endothelial Cells Cardiovascular drugs and therapy, 2026
- Comparative Incidence of Urinary Tract Infections in Diabetic Women Treated with Dapagliflozin Versus Empagliflozin: A Double-Blind Randomized Clinical Trial International journal of endocrinology and metabolism, 2026
- Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways Frontiers in pharmacology, 2026
- Efficacy and Safety of Empagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis Clinics and research in hepatology and gastroenterology, 2026
- Bioequivalence Evaluation of Immediate-Release Empagliflozin/Metformin Fixed-Dose Combination Tablets Under Fed Conditions in Healthy Mexican Subjects and Exploratory Analysis of Metformin Dose Proportionality Pharmaceuticals (Basel, Switzerland), 2026
- Hyponatremia correction is associated with increased brain-derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double-blind, placebo-controlled, crossover trial Journal of neuroendocrinology, 2026
- Empagliflozin: Therapeutic area: Kidney disease, nephrology: Reimbursement Review 2026
- Impact of Empagliflozin on Serum Calcium and Phosphate in Heart Failure Journal of cardiac failure, 2026
- SGLT2 Inhibition Attenuates Hippocampal Injury and Cognitive Impairment in Adult-Onset Hypothyroidism Journal of biochemical and molecular toxicology, 2026
- Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension Journal of the American Heart Association, 2026
- Empagliflozin in GSD-Ib: Long-term safety and sustained recovery of neutrophil function including NET formation Molecular genetics and metabolism reports, 2026
- Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies Frontiers in pharmacology, 2026
- Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells Journal of Cancer, 2026
- Empagliflozin targets a renal neuro-epithelial-immune axis in heart failure American Journal of Physiology - Cell Physiology, 2026
- Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy Cureus, 2026
- Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease Diabetes, obesity & metabolism, 2026
- Healthcare cost offsets associated with empagliflozin for the treatment of chronic kidney disease in Italy: a budget impact analysis Journal of nephrology, 2026
- Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation ESC heart failure, 2026
- Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial Journal of diabetes and its complications, 2026
- Empagliflozin inhibits the apoptosis of pancreatic β-cells through amelioration of endoplasmic reticulum (ER) stress Metabolism open, 2026
- Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis Frontiers in endocrinology, 2026
- A Digital Twin of Empagliflozin Pharmacokinetics and Pharmacodynamics Preprints.org, 2026
- Neutrophil-to-Lymphocyte Ratio in Patients With Heart Failure: Findings From The EMPEROR Program ESC heart failure, 2026
- Empagliflozin preserves mitochondrial function and reduces tubular injury in obese type 2 diabetic ZSF-1 rats bioRxiv (Cold Spring Harbor Laboratory), 2026
- Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis BMJ open, 2026
- Therapeutic Repositioning of SGLT2 Inhibitors Using Real-World Data: A Scoping Review of Emerging Indications and Rare Diseases 2026
- Center Composite Design Assisted Optimization of Rp-hplc Method for Simultaneous Estimation of Linagliptin and Empagliflozin Using Aqbd Perspective 2026
- Dronedarone hydrochloride reverses obesity-related metabolic syndrome while preserving skeletal muscle mass 2026
- Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway Frontiers in endocrinology, 2026
- Genetically nominated cardiovascular-kidney-metabolic features are not consistently more responsive to weight-loss and cardiometabolic interventions 2026
- Empagliflozin and Dapagliflozin in Improving Ejection Fraction: A Prospective Observational Comparison of Clinical Outcomes and Patient Reported Quality of Life Research Square, 2026
- Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study 2026
- Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study Diabetes care, 2026
- Empagliflozin protects against indomethacin-induced gastric injury in rats: evidence from inflammatory, apoptotic, and early PI3K/Akt/VEGF-related changes Inflammopharmacology, 2026
- Empagliflozin improves gut microbial disturbances and intestinal barrier integrity in STZ-induced type 2 diabetic mice The Journal of endocrinology, 2026
